LMNA and Cowden syndrome 1: Furthermore, remarkable advances are observed in experimental interventional strategies applicable for particular progeroid disorder such as gene editing procedures in HGPS (Beyret et al., 2019; Santiago-Fernandez et al., 2019; Koblan et al., 2021; Whisenant et al., 2022) and in CS (Wang et al., 2022), morpholino oligos to target aberrant splicing in HGPS (Osorio et al., 2011) and antisense oligonucleotides (ASOs) that reduce the levels of progerin transcripts (Puttaraju et al., 2021).